Clinical trials: End Stage Liver Disease
Hepatocellular Carcinoma in Hepatitis C Virus Infected Patients
Application of the Stem Cell Therapy in the End Stage Liver Disease and Assessment Its Consequences in the Quality of Live Style as Well as Development of HCC.
Prospective study to calculated the incidence of hepatocellular carcinoma in hepatitis C virus infected patients after stem cell therapy.
- Trial name
- NCT01729221
- Where
- Egypt
- Volunteers
- 280 people
- Sponsor
- Cairo University
Liver Failure
The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF
A randomized controlled trial to evaluate efficacy and safety of Thymosin-α1 administration in patients with HBV-related Acute-on-chronic liver failure.
- Trial name
- NCT03082885
- Testing
- Thymosin-α1
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Liver Transplantation (LT), End-stage Liver Disease (ESLD)
Restrictive Fluid Management In Liver Transplantation (REFIL)
The goal of the REFIL-2 study is to evaluate the effectiveness of a low splanchnic blood volume restrictive fluid management strategy (a strategy that involves limiting fluid administration and prioritizing the use of medications…
- Trial name
- REFIL-2 (NCT07695363)
- Testing
- Low splanchnic blood volume restrictive fluid management strategy, Phlebotomy, Optimized cardiac output liberal fluid management strategy
- Where
- 4 sites in Canada
- Volunteers
- 866 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Liver Cirrhosis, Fibrosis
Growth Hormone in Decompensated Liver Cirrhosis
Globally, cirrhosis and liver cancer carries a huge burden and accounts for about 3.5% (2 million) of all deaths every year. Once decompensated, i.e.
- Conditions
- Liver Cirrhosis, Fibrosis, End Stage Liver Disease, Digestive System Disease
- Trial name
- NCT05253287
- Testing
- Growth Hormone
- Where
- India
- Volunteers
- 96 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Acute-On-Chronic Liver Failure, Liver Cirrhosis
Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study
The definition and diagnostic criteria of acute-on chronic liver failure (ACLF) differed evidently between the East and the West due to the difference in the underlying etiology.
- Conditions
- Acute-On-Chronic Liver Failure, Liver Cirrhosis, Liver Transplant; Complications
- Trial name
- TEA-ACLF (NCT05036031)
- Volunteers
- 500 people
- Sponsor
- RenJi Hospital
Liver Transplantation, Tranexamic Acid
Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial
We propose a multi-center randomized trial to test the primary hypothesis that tranexamic acid is superior to placebo on blood loss in adult orthotopic liver transplantation within the initial 24 hours and that tranexamic acid is…
- Conditions
- Liver Transplantation, Tranexamic Acid, End-stage Liver Disease (ESLD)
- Trial name
- ESTA (NCT07157631)
- Testing
- tranexamic acid, 0.9 % saline
- Where
- China
- Volunteers
- 1,546 people
- Sponsor
- RenJi Hospital
Acute-On-Chronic Liver Failure
Identification and Verification of Neutrophil Extracellular Trap Net Related Markers in Acute-on-chronic Liver Failure
Acute-on-chronic liver failure (ACLF) refers to the acute deterioration of liver function in patients with chronic liver disease.
- Trial name
- NCT05909319
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
End Stage Liver Disease, Living Donor
Effect of Intermittent Hepatic Inflow Occlusion During Donor Hepatectomy In Living Donor Liver Transplantation
Intermittent hepatic inflow occlusion (IHIO), also called Pringle maneuver, is a safe and effective procedure for major hepatectomy in patients with liver disease.
- Trial name
- NCT01171742
- Testing
- Intermittent hepatic inflow occlusion (IHIO)
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Samsung Medical Center
End Stage Renal Disease, Chronic Hepatitis c
Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access
This is a single patient, single center study evaluating if administration of pan-genotypic DAA therapy on day 3 (+/- 2 days) post-kidney transplant prevents the transmission of hepatitis C virus infection from an HCV-positive…
- Trial name
- NCT04614142
- Testing
- Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Liver Transplantation
Assessment of a Quantra-guided Transfusion Algorithm in Liver Transplantation
Liver transplantation carries a substantial risk of bleeding, making precise haemostasis control essential, although assessing coagulation remains challenging.
- Trial name
- QUALIVERT (NCT06749405)
- Testing
- Transfusion algorithm based on Quantra®, Conventional transfusion algorithm
- Where
- France
- Volunteers
- 56 people
- Sponsor
- University Hospital, Toulouse
End Stage Liver DIsease
Disparities Among Liver Transplant Patients
The purpose of this study is to inform healthcare interventions to reduce the disparities in liver transplant listing and in transplantation.
- Trial name
- NCT05981196
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Acute-On-Chronic Liver Failure
To Assess the Efficacy of High-Volume Plasma Exchange and GCSF Versus GCSF Alone in Patients of Acute on Chronic Liver Failure (ACLF).
Study design-Open label randomized controlled trial Study period-2 years Study population-All patients of ACLF admitted to ILBS for a period of two years from Feb 2017 to Dec 2018 All the patients of ACLF will receive standard…
- Trial name
- NCT03162419
- Testing
- Standard Medical Therapy, Plasma Exchange, GCSF
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatitis C, Chronic
A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment
This study will evaluate the pharmacokinetics (area under the curve [AUC], maximum concentration [Cmax], and other parameters) and tolerability of peginterferon alfa-2a and ribavirin combination therapy following single and…
- Trial name
- NCT02864199
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 17 sites in United States, Brazil and 3 more
- Volunteers
- 63 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Infection, End Stage Renal Disease
Boceprevir in End Stage Renal Disease (ESRD)
The purpose of the study is to assess the safety and efficacy of triple therapy with pegylated interferon (P-IFN), ribavirin and boceprevir in patients with genotype 1 chronic Hepatitis C Virus (HCV) infection and end stage renal…
- Trial name
- NCT02112630
- Testing
- P-IFN alfa 2a, P-IFN alfa 2b, Ribavirin
- Sponsor
- Columbia University
End Stage Renal Disease, End Stage Liver Disease
Transplant Patient Registry of Liver, Kidney and/or Pancreas
This is a registry of data collected from patient records, both of those who have a condition which may require transplantation and those who have undergone transplantation of the liver, kidney and/or pancreas.
- Trial name
- NCT00238693
- Where
- United States
- Volunteers
- 13,767 people
- Sponsor
- Virginia Commonwealth University
Acute on Chronic Liver Failure, Traditional Chinese Medicine
Study on the Optimal Strategy for Acute-on-chronic Liver Failure With Integrative Treatment
Background: Acute-on-chronic liver failure (ACLF) is a syndrome characterized by acute deterioration in the setting of chronic liver disease associated with high short-term mortality.
- Conditions
- Acute on Chronic Liver Failure, Traditional Chinese Medicine, Hepatitis B
- Trial name
- NCT03577938
- Testing
- Chinese herbal medicine, Control (blank)
- Where
- 15 sites in China
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- Beijing 302 Hospital
Liver Failure, Kidney Failure
Mesenchymal Stem Cells After Renal or Liver Transplantation
The immune system of a patient can attack the liver or the kidney received from a donor (organ rejection). This can be prevented by treating these patients long-life with immunosuppressive drugs.
- Trial name
- NCT01429038
- Testing
- Mesenchymal Stem Cells
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- University of Liege
End-stage Liver Disease (ESLD), Cirrhosis, Liver
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and…
- Conditions
- End-stage Liver Disease (ESLD), Cirrhosis, Liver, Cirrhosis, Decompensated, Liver Diseases
- Trial name
- EMERALD (NCT06823713)
- Testing
- RTX001
- Where
- 15 sites in Spain, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Resolution Therapeutics Limited
End Stage Liver Diseases
Analysis of Respiratory System Mechanics and Inflammatory Response During Orthotopic Liver Transplantation (SPPLIT Trial)
During orthotopic liver transplantation (OLT), respiratory system function may be severely impaired for several reasons including anaesthesia effects, hyperdynamic volume state with fluid overload and ischemia reperfusion injury.
- Trial name
- SPPLIT (NCT02119585)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Turin, Italy
Acute-On-Chronic Liver Failure
TAK-242 in Patients With Acute Alcoholic Hepatitis
A phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of TAK-242 in subjects with acute decompensation of…
- Trial name
- NCT04620148
- Testing
- TAK-242
- Where
- 3 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- Akaza Bioscience Ltd